Analyst: Biotechs could suffer if lawsuits were to come

09/15/2005 | Forbes

Biotechs may be on the sidelines in lawsuits against Merck and Johnson & Johnson for Vioxx and Ortho-Evra, respectively, but biotechs faced with similar billion-dollar challenges could be wiped out, according to one analyst. He said he cannot envision a case in which a biotech, with an average value only about $1 billion, could shield itself against a similar legal onslaught, but could see a situation in which biotechs feel they have to merge to build an entity large enough to withstand such challenges.

View Full Article in:

Forbes

Published in Brief: